bedinvetmab sold brand name librela canine monoclonal antibody used control pain associated osteoarthritis librela sponsored common side effects include increased blood urea nitrogen indicator kidney function urinary tract infection bacterial skin infection skin irritation dermatitis rash erythema pain injection site vomiting emesis weight loss bedinvetmab approved medical use european union november united states may bedinvetmab first monoclonal antibody approved united states controlling osteoarthritis pain bedinvetmab indicated alleviation pain associated osteoarthritis two field studies conducted evaluate effectiveness bedinvetmab one united states one european studies enrolled clientowned dogs diagnosed half dogs received bedinvetmab half dogs received sterile saline injection every days total three treatment various days throughout study owners used canine brief pain inventory cbpi assessment tool measure severity dogs pain degree pain interfered dogs daily weight evidence two field studies demonstrated bedinvetmab effective controlling pain associated osteoarthritis dogs least two doses given days bedinvetmab international nonproprietary article incorporates public domain material united states department health human services veterinary article stub help wikipedia expanding ithttpsenwikipediaorgwikibedinvetmab